UAL
43
11
FITB
59
3
EBAY
62
9
ED
45
2
TMO
40
2
ZTS
19
3
TRV
34
-12
STI
29
5
SJM
11
5
SYF
72
3
XYL
49
2
AMP
46
3
TDC
49
-5
HON
62
10
LNC
48
5
GS
62
-10
BAC
53
2
GLW
53
-2
APA
46
-2
HIG
59
3
UAL
43
11
FITB
59
3
EBAY
62
9
ED
45
2
TMO
40
2
ZTS
19
3
TRV
34
-12
STI
29
5
SJM
11
5
SYF
72
3
XYL
49
2
AMP
46
3
TDC
49
-5
HON
62
10
LNC
48
5
GS
62
-10
BAC
53
2
GLW
53
-2
APA
46
-2
HIG
59
3
Financhill
Back

Zevra Therapeutics 10K Form

Sell
41

ZVRA
Zevra Therapeutics

Last Price:
$9.02
Seasonality Move:
26.33%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ZVRA News And Ratings

See the #1 stock for the next 7 days that we like better than ZVRA

ZVRA Financial Statistics

Sales & Book Value

Annual Sales: $23.6M
Cash Flow: $-8.3M
Price / Cash Flow: 0
Annual Sales: $0.75
Price / Book: 12.05

Profitability

EPS (TTM): -1.92000
Net Income (TTM): $-92M
Gross Margin: $16.2M
Return on Equity: -198.46%
Return on Assets: -54.88%

Zevra Therapeutics Earnings Forecast

Key Zevra Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for ZVRA is 68.59%.
  • The Selling, General & Administrative Expenses for ZVRA have been equal to 232.37% of Gross Profit Margin.
  • The Research & Development expenses have been 178.28% of Revenue.
  • The Net Earning history of ZVRA is -446.85% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 5 years.

Zevra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ZVRA
Website: zevra.com

Debt

Debt-to-Equity Ratio: 1.46
Current Ratio: 3.02
Quick Ratio: 2.79

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 14.03

ZVRA Technical Analysis vs Fundamental Analysis

Sell
41
Zevra Therapeutics (ZVRA) is a Sell

Is Zevra Therapeutics a Buy or a Sell?